The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design

Table 6 Mean cognitive function by follow-up time point and according to donepezil added to stimulation therapy versus placebo added to standard care

Groups	Time points
	Baseline n = 87	4 months n = 76	8 months n = 74	12 months* n = 69	p-value¹	p-value²
MMSE ± SD**
Donepezil + stimulation therapy	22.9 ± 4.5	22.9 ± 4.5	22.9 ± 4.9	22.5 ± 5.5	0.443	0.449
Placebo + standard care	23.3 ± 4.9	23.8 ± 4.2	23.6 ± 4.6	24.1 ± 4.7
Clock Drawing Test ± SD**
Donepezil + stimulation therapy	2.9 ± 1.1	2.9 ± 1.1	2.8 ± 1.2	3.1 ± 1.0	0.064	0.035
Placebo + standard care	2.9 ± 1.2	3.2 ± 1.0	3.3 ± 1.0	3.3 ± 1.1
ADAS-cog ± SD**
Donepezil + stimulation therapy	19.3 ± 8.7	19.2 ± 8.2	17.2 ± 9.5	16.1 ± 8.7	0.554	0.458
Placebo + standard care	17.2 ± 8.0	16.3 ± 7.1	16.3 ± 8.5	15.1 ± 7.9

* n varies due to missing values ** Standard deviation. p-value¹ = Equal time trends between groups. p-value² = Equal time trend between groups adjusted for baseline cognitive function.

ISSN: 1471-2377